Global Small Molecule API Market: Snapshot
Over the past ten years, the attention of pharmaceuticals world over has veered off from goldmine of opportunities found in large molecules biologics to small molecules APIs. The shift has been slow but steady: small-molecule pharmaceuticals accounted for as much as 82% of all new molecule entities (NMEs) approvals in 2014. The number climbed to 71%, or 42 to be precise, of all NMEs approved by the U.S. FDA alone. The trend underscores resurging interest in small molecules, hence pushing the prospects of the small molecule API market to a new level.
With small molecule API holding a majority of drug development pipeline and growing numbers of NME approvals, the small molecule API market has been making steady evolution. Over the past few years, growing nod by the FDA for various drug approvals points to a potentially encouraging trend for the expansion of the small molecule API market. Some of the key product development pipeline primarily utilizing small molecule API include kinase inhibitors and anti-retroviral products.
A report on the global small molecule API market strives to take a holistic look on the various growth dynamics, emerging opportunities, and major drug pipeline investments. The analysis also highlights key production capacity expansions made by players in the small molecule API market.
Get an Idea about the Offerings of Our Small Molecule API Market Report from this Brochure
Global Small Molecule API Market: Regional Analysis
Numerous big pharma companies with the likes of Pfizer and AbbVie and a few and biotechnology companies have been pitching for NME approvals that include small molecules API. This alone underscores the vast potential of the small molecule API market.
For instance, Pfizer, a prominent biopharmaceutical companies worldwide, has made bagged four NME approvals: Daurismo (glasdegib), Lorbrena (loratinib), Talzenna (talazoparib), Vizimpro (dacomitinib). All of these were small molecule APIs. Even generic drug makers are searching for new revenue streams in the small molecule API market. A case in point is Mylan who bagged a NME approval for its small molecule Yupelri in 2018. The medication is used for treating chronic obstructive pulmonary disease (COPD).
An renowned American pharmaceutical company Eli Lilly announced in January 2019 that it was acquiring Loxo Oncology. With this, the company intended to fork out $8 billion on the pipeline of drugs that can be used for treating rare cancers. Such measures are opening new avenues in the small molecule API market.
Request the Coronavirus Impact Analysis on this Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73180
Some of the prominent players operating in the small molecule API market are
- Johnson & Johnson
- AstraZeneca
- Bachem Holding AG
- Bristol-Myers Squibb
- Sanofi S.A.
Pre Book _ Research Report Now – https://www.transparencymarketresearch.com/checkout.php?rep_id=73180<ype=S
Global Small Molecule API Market: Growth Dynamics
A large part of anti-cancer drugs in the healthcare industry are utilizing the potential of small molecule APIs, probably owing to several advantages these have over advantages over large molecules. Continuously expanding arsenal of oncology drugs in developing and developed countries over the world is bolstering the prospects of the small molecule API market. The growth has been largely supported by parallel advances in chemical manufacturing technologies over the last ten years.
More Trending Reports by Transparency Market Research – http://www.prnewswire.com/news-releases/serious-lack-of-donors-of-organs-is-helping-to-increasing-popularity-of-heart-pump-devices-market-valuation-to-rise-up-to-us4-3-bn-by-2027–notes-tmr-301026081.html
